Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidate.

We conducted a Phase I randomized, dose-escalation, route-comparison trial of MVA-CMDR, a candidate HIV-1 vaccine based on a recombinant modified vaccinia Ankara viral vector expressing HIV-1 genes env/gag/pol. The HIV sequences were derived from circulating recombinant form CRF01_AE, which predomin...

Descripció completa

Dades bibliogràfiques

Autors principals:	Jeffrey R Currier, Viseth Ngauy, Mark S de Souza, Silvia Ratto-Kim, Josephine H Cox, Victoria R Polonis, Patricia Earl, Bernard Moss, Sheila Peel, Bonnie Slike, Somchai Sriplienchan, Prasert Thongcharoen, Robert M Paris, Merlin L Robb, Jerome Kim, Nelson L Michael, Mary A Marovich
Format:	Artigo
Idioma:	Inglês
Publicat:	Public Library of Science (PLoS) 2010-11-01
Col·lecció:	PLoS ONE
Accés en línia:	http://europepmc.org/articles/PMC2981570?pdf=render
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!